Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 121, Issue 1, Pages 132-147Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI42912
Keywords
-
Categories
Funding
- AstraZeneca makers [ZD4054]
- NIH [CA143971]
- NATIONAL CANCER INSTITUTE [R01CA143971] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Many patients with advanced bladder cancer develop lethal metastases to the lung The vasoconstricting protein endothelin-1 (ET-1) has been implicated m this process, although the mechanism(s) by which it promotes metastasis remains unclear Here, we have evaluated whether tumor ET-1 expression can serve as a biomarker for lung metastasis and whether it is required for metastatic disease Evaluation of ET-1 mRNA and protein expression m four patient cohorts revealed that levels of ET-1 are higher in patients with muscle-invasive bladder cancers, which are associated with higher incidence of metastasis, and that high ET-1 levels are associated with decreased disease-specific survival Consistent with its proinflammatory activity, we found that tumor-derived ET-1 acts through endothelin-1 receptor A (ETAR) to enhance migration and invasion of both tumor cells and macrophages and induces expression of inflammatory cytokines and proteases Using human and mouse cancer cells depleted of ET-1 and pharmacologic blockade of ET receptors m lung metastasis models, we found that tumor ET-1 expression and ETAR activity are necessary for metastatic lung colonization and that this process is preceded by and dependent on macrophage infiltration of the lung In contrast, tumor ET-1 expression and ETAR activity appeared less important in established primary or metastatic tumor growth These findings strongly suggest that ETAR inhibitors might be more effective as adjuvant therapeutic agents than as initial treatment for advanced primary or metastatic disease
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available